Physician profile
Mary Proctor
NPI 1144779158
$1,829.78
in general payments reported to CMS, 2019-2025
24 companies · $788 in 2025
The $788 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $353 · 2023: $455 · 2024: $108 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $363.03 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $167.21 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $152.83 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Regeneron Healthcare Solutions, INC. | $120.15 | 2023 | Dupixent |
| Merck Sharp & Dohme LLC | $117.17 | 2022-2023 | Verquvo, Belsomra, Steglujan |
| Mylan Specialty L.P. | $114.41 | 2023 | Yupelri |
| Sumitomo Pharma America, INC. | $88.36 | 2025 | Gemtesa |
| Amgen INC. | $83.70 | 2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $78.24 | 2022-2025 | Trelegy Ellipta |
| Corcept Therapeutics | $69.45 | 2025 | Korlym |
| Abbott Laboratories | $67.43 | 2023-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $60.31 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.02 | 2022 | |
| Pfizer INC. | $51.75 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $41.11 | 2022-2024 | Eliquis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $39.49 | 2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $32.48 | 2023 | Hetlioz |
| Verona Pharma, INC. | $25.20 | 2025 | Ohtuvayre |
| Horizon Therapeutics Plc | $20.82 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.49 | 2021 | |
| Gilead Sciences, INC. | $17.38 | 2025 | |
| Esperion Therapeutics, INC. | $15.38 | 2025 | Nexletol |
| Seqirus USA INC | $15.08 | 2025 | Fluad, Flucelvax |
| Otsuka America Pharmaceutical, INC. | $14.29 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Proctor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.